Leprosy is a chronic infection caused by the bacteria Mycobacterium leprae or Mycobacterium lepromatosis causing granulomas of the nerves, respiratory tract etc. The granulomas may result in lack of ability to feel pain, especially in the extremities such as finger tips. The leprosy treatment market is falling due to early detection and awareness campaigns and integration of basic leprosy services into general health services of many countries.
Considering all these factors the Leprosy treatment market is expected to reach USD 3.5 billion by the end of 2023, Leprosy treatment market is projected to growing at a CAGR of ~ 3.2% during 2017-2023.
Sources: World Health Organization (WHO), National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centre for Health Informatics, India
Key players of Leprosy treatment Market:
Key players profiled in the report are Glaxo Smithcline, Systopic Laboratories Pvt. Ltd., Cadila Pharmaceuticals, Acme Pharmaceuticals, Macleods Pharmaceuticals, Novartis International AG, Astra Zeneca, Lark Laboratories Ltd., and others.`
Leprosy treatment Market Segments:
The leprosy treatment market is segmented on the basis of drug class, disease type and market channel. Based on drug class, the market has been segmented as sulfone, phenazine, derivative, anti-tubercular drugs and others. Based on the disease type, the leprosy treatment market has been segmented as paucibacillary leprosy, multibacillary leprosy. Based on the end users, the leprosy treatment market has been segmented as private, contract and others.
Figure 1 Leprosy treatment Market by Market Channel, 2016 (% Market Share)
US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. The faster market uptake of new technology in the US is also an important driver of the market for global leprosy treatment. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most potential and it is estimated to be led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa are expected to be a laggard due to poor economic and political conditions and poor healthcare penetration.
The report for Leprosy treatment Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
|Forecast Units||Value (USD Billion)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Drug class, Disease type and Market channel|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Glaxo Smithcline, Systopic Laboratories Pvt. Ltd., Cadila Pharmaceuticals, Acme Pharmaceuticals, Macleods Pharmaceuticals, Novartis International AG, Astra Zeneca, Lark Laboratories Ltd., and others|
|Key Market Opportunities||
|Key Market Drivers||Increasing prevalence of skin diseases|
The Valuation by 2023 Would be USD 3.5 Billion.
The Projected CAGR For The Leprosy Treatment Would Be 3.2% During The Forecast Period Of 2017-2023.
The Disease Type Includes Paucibacillary Leprosy And Multibacillary Leprosy.
The Drug Types Are Phenazine, Sulfone, Anti-Tubercular Drugs, Derivative, And Others.
The Players Are Systopic Laboratories Pvt. Ltd., GlaxoSmithKline, Acme Pharmaceuticals, Cadila Pharmaceuticals, Novartis International AG, Astra Zeneca, Macleods Pharmaceuticals, Lark Laboratories Ltd., and others.